Introduction
The 5-HT1A receptor, a type of serotonin receptor, is predominantly located within the limbic and cortical regions of the brain. It holds the distinction of being the first identified serotonin receptor and one of the most widely expressed one. The behaviour of the 5-HT1A receptor is crucial not only for understanding the neurological impact of Selective Serotonin Reuptake Inhibitors (SSRIs) but also a broad spectrum of other psychiatric medications including anxiolytics and antipsychotics.
Recent research highlights the pivotal role of the 5-HT1A receptor, not only in the therapeutic effects of many psychiatric medications – but also in their side effects. This receptor has a critical regulatory influence on a range of functions, including cognition, libido, mood, and even hormonal balance (read more). However, the 5-HT1A receptor’s mechanisms are complex, making it difficult to summarise concisely. Nevertheless, my goal here is to present the latest scientific findings in a clear, accessible way for readers with limited biology backgrounds. In this post, I’ll explain how SSRIs interact with this serotonin receptor to bring about lasting changes in sexual function, cognition, and mood.
What is an SSRI?
SSRI is short for selective serotonin reuptake inhibitor, and this precisely what this class of medication aims to do, inhibit the reuptake of serotonin. The significance of the first ‘S’ in SSRI comes from the distinction from older generations of antidepressants which had many binding sites aside from the serotonin transporter. The goal of SSRIs is to boost the activity of serotonin in the brain. This neurotransmitter in particular has long believed to be responsible for mediating feelings of happiness, making it an enticing target for pharmaceuticals combatting depression. The serotonin hypothesis of depression stems from the evidence that patients suffering from major depressive disorder have significantly lower levels of blood platelet serotonin. [26]
Furthermore, depressed patients also have lower levels of L-tryptophan, the precursor to serotonin, in the blood plasma. [27] Adding to this picture was research showing that a depressive state could be induced in patients by feeding them a tryptophan depleted diet, thereby preventing the natural synthesis of serotonin in the body. [28] Of course, there are other neurotransmitters that impact mood like Dopamine and Norepinephrine, however the abundance of early scientific evidence favouring the connection between serotonin and depression paved the way for generation of pharmaceuticals.
Neurotransmitters, such as Serotonin, are like chemical messengers that are released from presynaptic neurons across a synapse to a postsynaptic neuron, where it can affect mood and cognition. Once these neurotransmitter have crossed over the synapse they bind to certain receptor sites on the postsynaptic neuron. After this signal has been transmitted to the post synaptic neuron, the neurotransmitter is taken back to the presynaptic neuron via protein called SERT, also known as the serotonin transporter. This process of reabsorption allows the neurotransmitter to be recycled or broken down. SSRIs inhibit the action of SERT, the serotonin transporter, in order to enhance the effect of Serotonin on the postsynaptic neuron. It’s through this means that SSRIs aim to improve mood and resolve symptoms of depression. [29]
A crucial component in considering how Serotonin will impact mood and cognition is the variety of different serotonin receptors distributed in different neurons throughout the brain. A blanket approach of simply increasing Serotonin throughout the brain doesn’t consider the fact that serotonin can have very different effects on neurons depending on what type of serotonin receptor they expressed. The primary target receptor is 5-HT1A, which is the first receptor type to be sequenced as well as being among the most abundant. [30]
What is the 5-HT1A receptor?
The 5-HT1A receptor is a serotonin receptor, which means its bound by the neurotransmitter serotonin to exert its effects. As previously explained, SSRIs boost the effect of serotonin by preventing it from being reabsorbed too quickly by the serotonin transporter. However, since SSRIs were first introduced medical paradigms have shifted in favour of theories of depression centred on ‘neurogenesis’ (the growth of new neurons).
The 5-HT1A receptors are inhibitory receptors. This is evidenced by a reduction in AMPA evoked currents when bound by serotonin (AMPA receptors are bound by the excitatory neurotransmitter glutamate). Binding the 5-HT1A receptor suppresses neuronal activity through a variety of mechanisms involving potassium channel activation and calcium channel inhibition. By causing a neuron to become Hyperpolarised, it won’t reach it’s action potential and therefore fails to initiate transmission.
Original by en:User:Chris 73, updated by en:User:Diberri, converted to SVG by tiZom, CC BY-SA 3.0, via Wikimedia Commons
A key feature of the G-protein coupled receptors like 5-HT1A is that they undergo a process of receptor internalisation after prolonged periods of activation. This process involves the receptor being removed from cell surface and taken into the cell thereby desensitising the receptor. This process is particularly important for understanding SSRIs work.
Autoreceptor vs. Heteroreceptor
The receptor is subdivided into two types with different distributions within the brain: (presynaptic) autoreceptors and (post synaptic) heteroreceptors. The autoreceptors are localised within the brain stem in a structure called the Raphe Nuclei, and it’s from this structure in the middle of the brain that all other serotonergic neurons project outward.
As the name might suggest, the autoreceptor serves to self-regulate serotonin transmission out into the rest of the brain through a process of negative feedback. When serotonin over-accumulates within the Raphe Nuclei it binds to these autoreceptors to then limit further serotonin release – since 5-HT1A receptors are inhibitory. As autoreceptors have a self-limiting effect on serotonin transmission, their overexpression limits serotonin release to other areas of the brain. Notably, an overexpression of the autoreceptor and is often identified in autopsies from patients with depression, for reasons that will become evident later in the article. [1]
The post-synaptic heteroreceptor sites are distributed in the limbic and cortical regions. The limbic system is responsible for regulating emotion, learning and sexual behaviour. Like the presynaptic autoreceptor, binding at the 5-HT1A heteroreceptor triggers hyperpolarisation of that neuron. Hyperpolarisation is the process by which in the inside of the neuron becomes more negatively charged, and thus makes it less likely to fire. Through this mechanism that 5-HT1A reduces neuronal activity in targeted brain structures.
Based on the description so far, one might conclude that serotonin binding to heteroreceptors would produce the same reduction in neuronal activity in these limbic and cortical structures. However, the reality is more complex, as heteroreceptors are present on two different types of neurons with opposing effects: interneurons and pyramidal neurons.
The interneurons are GABAergic, meaning they release the inhibitory neurotransmitter GABA. [2] Conversely, pyramidal neurons release excitatory neurotransmitters such as glutamate and dopamine. They are particularly abundant in the cerebral cortex, making them especially important for motivation and executive functioning.
These excitatory pyramidal neurons are opposed by the GABAergic interneurons that feed into them. Understanding how binding to the 5-HT1A heteroreceptor will impact mood therefore depends on the relationship between these two opposing sets of neurons. Consider a hypothetical medication that very selectively targets the heteroreceptor at the interneurons. By lowering the transmission of GABA, it would in fact disinhibit dopamine and glutamate in the cortex, rather than simply have a suppressive effect.
Autoreceptors:
- These pre-synaptic receptors are distributed in the brain stem and negatively regulate 5-HT release to cortical and limbic structures.
Heteroreceptor:
- Interneurons are GABAergic, binding at the 5-HT1A receptor on these neurons lowers the release of GABA to have an activating effect.
- Pyramidal neurons are primarily glutamatergic and are distributed in the frontal cortex. Binding to the heteroreceptor sites on these glutamatergic and dopaminergic neurons would have a suppressive effect.
“Creative Commons, Sagittal Graphic, Servier / Modified from original image with added graphics to indicate 5-HT1A Circuitry”
Interneurons Control Cortical Activity
Given the complexity of the 5-HT1A receptor, medications acting upon it can sometimes behave in counterintuitive ways. Buspirone is the most common medication classified as a 5-HT1A agonist (an agonist being a molecule that mimics serotonin in this instance). Buspirone is often prescribed as an anti-anxiety medication. This seems logical, as anxiety is associated with overactivity in cortical layers, and so binding to the heteroreceptors within the prefrontal cortex would supposedly suppress this activity.
As it turns out, Buspirone actually increases activity in the prefrontal cortex and enhances dopamine and glutamate release.[3] Curiously, this actually gives it some additional applications as a cognitive enhancer. The reason for this potentially confusing effect is because the inhibitory action of Buspirone on the GABAergic interneurons predominates, and the subsequent reduction in firing rate of these inhibitory neurons enhances cortical glutamate activity.
The anti-anxiety effects of Buspirone, however, are more likely due to its ability to quiet activity in limbic structures such as the amygdala, rather than the prefrontal cortex. Since heteroreceptors are present on both the interneurons and pyramidal neurons, and because the suppressive effect of 5-HT1A binding on the interneurons predominates within the prefrontal cortex, a selective heteroreceptor agonist can be considered stimulating and conducive to dopamine and glutamate release.
SSRIs (Selective Serotonin Reuptake Inhibitors) are the first-line treatment for major depressive disorder and are primarily understood to act through the 5-HT1A receptor. When serotonin accumulates within the autoreceptor site, it triggers negative feedback to block further release of serotonin. This presents another perplexing quirk of the 5-HT1A receptor: a build-up of serotonin at the autoreceptor would, in theory, limit serotonin release to the rest of the brain through its negative feedback mechanism.
However, these autoreceptors undergo desensitization with chronic exposure to SSRIs, and eventually, their inhibitory effect is blocked, which allows for even greater serotonin transmission. Since SSRIs essentially rely on disabling the autoreceptor, it has been found that pre-treatment with a 5-HT1A antagonist (such as Pindolol) accelerates the antidepressant effect of SSRIs.[4]
SSRI Treatment Downregulates the Heteroreceptor
The contrasting effects of binding at the heteroreceptor versus the autoreceptor were most clearly demonstrated in a 2017 study by Garcia-Garcia. They took two different groups of mice and removed either the 5-HT1A heteroreceptors or autoreceptors. They discovered that the mice lacking heteroreceptors displayed depressive symptoms that were characteristic of anhedonia – but didn’t display symptoms of anxiety.
Conversely, the mice that had their autoreceptors ablated experienced heightened anxiety but still maintained a hedonic drive. [5] This study perhaps gives most clearly confirms the importance of the heteroreceptor in mediating feelings of reward and hedonic drive. Substantiating this notion is the fact that the medication Flibanserin, which is used to treat hypoactive sexual disorder, selectively binds to the heteroreceptor, boosting hedonic drive, particularly in relation to sexual stimuli. [6]
The loss of the heteroreceptor and the ensuing anhedonic symptoms in the Garcia-Garcia study poignantly mirror the adverse effects of SSRI treatment in some patients. As described previously, treatment with SSRI’s eventually causes a desensitisation of the autoreceptor. This in theory should allow for greater serotonin transmission to the 5-HT1A heteroreceptor. Whilst this is true for at least some period of time, it doesn’t explain the efficacy of SSRI’s in treating anxiety conditions – since autoreceptor knock-out mice display more anxiety.
As in turns out, prolonged SSRI treatment eventually causes desensitisation in the heteroreceptor too. [7] In fact, the heteroreceptor knockout mice are observed to have the same pattern of reduced prefrontal cortex activity when compared against mice treated with the SSRI paroxetine.[8][9] This study also linked the reduction in cortical activity to symptoms of anhedonia and behavioral despair.
How 5-HT1A Influences Sexual Functioning
As I’ve alluded to periodically throughout this article, the 5-HT1A heteroreceptor is important in regulating sexual behaviour. This is particularly relevant in cortical areas such as the orbitofrontal cortex. Hyperactivity within the orbitofrontal cortex is even linked to hypersexuality, and compulsive behaviour. [10] The link between sexuality and compulsive behaviour is an important one, being tied together by the 5-HT1A heteroreceptor.
Chronic SSRI treatments have been found to be effective in treating OCD (obsessive compulsive disorder), an effect in part mediated desensitising the 5-HT1A heteroreceptors within the orbitofrontal cortex. [11] Reducing activity within this region also predicts the inhibitory effect of SSRIs on sexual behaviour. Considering the role of the frontal cortex in reward perception, it’s plausible that the suppressive effect of SSRIs on sexual behaviour could be partly due to a decreased sense of reward.
However there are other means by which the 5-HT1A could be influencing libido, such as by inhibiting neuronal-Nitrous Oxide synthase (nNOS) (which plays a role in sexual behaviour in both men and women). Many serotonergic neurons in the Raphe Nuclei produce nitric oxide, and the application of 5-HT1A agonists to autoreceptors in this area can inhibit nNOS production.[12]
Interestingly, this interaction might also contribute to the anti-anxiety effects observed with non-selective 5-HT1A agonists and SSRIs. [13][14] Another important pathway influenced by the 5-HT1A receptor is the mu-opioid receptor (MOR), which is tightly linked to the pleasure of sexual experience. The presence of MOR in the brain predicts a higher frequency of engaging sexual activity. [15]
Restoring the 5-HT1A Receptor
Having elucidated the normal functioning of the 5-HT1A receptor and the alterations caused by SSRI treatment, I can now delve into the subject of therapeutic interventions. It becomes apparent from this article that conventional treatments for depression, such as Selective Serotonin Reuptake Inhibitors (SSRIs), are not universally effective.
While SSRIs do promote the desensitization of autoreceptors, thereby enhancing serotonin release in the brain, their effectiveness is limited due to a consequent desensitization at post-synaptic heteroreceptor sites. For some people SSRIs might even aggravate an anhedonic depressive state, which could be attributed to the reduced activation of 5-HT1A heteroreceptor sites on GABAergic interneurons. How an individual will respond to SSRI treatment appears to rely on specific genetic vulnerabilities.
A crucial regulator of 5-HT1A expression is the transcription factor Deaf1, which exerts a dual effect by inhibiting autoreceptor expression and enhancing heteroreceptor expression. The binding efficiency of this transcription factor is influenced by a polymorphism on the SNP rs6295.
People with the G allele exhibit reduced Deaf1 binding, leading to the adverse effects associated with increased autoreceptor expression and lower heteroreceptor expression. [16] Notably, the G allele occurs more frequently in individuals with depression. This presents a plausible genetic risk in developing PSSD, with a greater risk of desensitisation of the heteroreceptor. The G-allele frequency is around 30% in Europeans, and so a GG genotype would represent around 10% of a European population. [25]
A medication notable for modulating Deaf1 is Lithium, through its suppressive effects on GSK3β (read more). Lithium boosts the expression of the post-synaptic heteroreceptor 5-HT1A while repressing the autoreceptor. In the context of the G allele polymorphism, the efficacy of Flibanserin (a post-synaptic 5-HT1A receptor agonist) is significantly reduced.
Furthermore, patients with this polymorphism show also have worse responses to SSRIs. Whilst this is typically attributed to a resilience to autoreceptor desensitisation, it’s possible that it could expose a greater vulnerability to heteroreceptor desensitisation in inducing anhedonic symptoms.[17]
Conclusion
An optimal strategy for mitigating the symptoms associated with increased autoreceptor expression would involve inhibiting activity at the autoreceptor while simultaneously boosting activation at the heteroreceptors – particularly on GABAergic interneurons so as to disinhibit cortical activity in the prefrontal cortex.
Pindolol is a beta-blocker which has consistently been shown to function as an autoreceptor antagonist. It can be used to augment serotonin transmission to expedite the therapeutic effects of Selective Serotonin Reuptake Inhibitors (SSRIs). [18] Intriguingly, there is evidence suggesting that the beneficial effect may continue for some time after cessation of the medication. [19]
Furthermore, the combined use of 5-HT1A antagonists and SSRIs has even been found to prevent and reverse SSRI induced sexual dysfunction in animal studies. Reseachers found that chronic 14-day treatment with the SSRI fluoxetine resulted in significant impairments to sexual function in male rats. A 5-HT1A autoreceptor antagonist similar to Pindolol called WAY-101405 completely reversed Fluoxetine’s effect on erectile function. Long term co-administration of the 5-HT1A antagonist with Fluoxetine was also protective against sexual dysfunction, without impacting the efficacy of the antidepressant and without signs of tolerance. [20] The reason Pindolol might be a more desireable approach in overcoming the autoreceptor is that it doesn’t result in receptor internalisation in the way chronic SSRI treatment does alone. [24]
An alternative method for influencing 5-HT1A receptor expression involves the use of Histone Deacetylase (HDAC) inhibitors. These epigenetic agents inhibit the removal of acetyl groups from histones, thereby facilitating gene expression. Acetyl groups (Ac) on histone tails maintain an open chromatin structure (Euchromatin) which is necessary for gene transcription. Butyrate, a naturally occurring HDAC inhibitor, has been observed to elevate the mRNA levels of the 5-HT1A heteroreceptor in the hypothalamus (read more). [21]
modified from original byAnnabelle L. Rodd, Katherine Ververis, and Tom C. Karagiannis, CC BY-SA 4.0, via Wikimedia Commons
Notably, when used in conjunction with estrogen, butyrate demonstrated an antidepressant effect. [22] This finding underscores the intricate relationship between HDAC inhibition and the 5-HT1A receptor, with growing evidence indicating that the 5-HT1A receptor is both influenced by and influences histone modifications. What isn’t clear is how Butyrate may affect pre-synaptic 5-HT1A receptors.
Research has shown that activation of 5-HT1A heteroreceptor sites in the hippocampus promotes gene expression through the acetylation of H3 and H4 histones. Additionally, studies have revealed that the HDAC inhibitor Trichostatin A can mimic the antidepressant effects of 5-HT1A agonism, effecting similar modifications in gene expression. [23] These findings highlight the complex interplay between epigenetic regulation and serotonin receptor activity in managing depressive symptoms.
Article Summary
- Serotonin is a neurotransmitter in the brain that functions as a messenger. It attaches to specialized sites known as serotonin receptors. Upon binding to these receptors, serotonin initiates a range of processes related to mood, emotion, and cognition. There are various types of serotonin receptors located in different areas of the brain, each mediating distinct effects. Among these, the 5-HT1A receptor is one of the most prevalent.
- The 5-HT1A receptor is particularly relevant to cognition, libido, and depression. The behaviour of this receptor can be understood in terms of its two subtypes: heteroreceptor and autoreceptor. The autoreceptor is found with a region of the brain stem called the Raphe Nuclei, and when bound to by serotonin it blocks the further release of serotonin to the rest of the brain. An overexpression of this type of serotonin receptor is linked to depression. Conversely, binding at the heteroreceptor is beneficial for mood and cognition and facilitates sexual behaviour.
- Medications that bind to these receptors that mimic the effect of serotonin are called agonists. A common agonist of the 5-HT1A receptor is called buspirone, and has antidepressant, pro-cognitive and even libido enhancing effects. Similarly, the medication Flibanserin is used to treat women with hypoactive sexual desire through its effects at the 5-HT1A heteroreceptor.
- SSRI treatment has been traditionally believed to target the autoreceptors. The initial increase in the abundance of serotonin paradoxically reduces the release of serotonin from the Raphe Nuclei through negative feedback at the autoreceptors. Eventually however these autoreceptors desensitise which floods the brain with serotonin.
- More recent research has indicated that ultimately the heteroreceptors also undergo the same desensitisation and their beneficial effects on cognition and libido are diminished. Researchers have discovered that ablation of heteroreceptors leads to a state of anhedonia and apathy. A comparable effect is also noted following prolonged use of SSRIs (Selective Serotonin Reuptake Inhibitors), which results in desensitization of the heteroreceptor.
- A decrease in binding at these heteroreceptors is associated with lowered cortical activity.The prefrontal cortex plays a crucial role in assessing perceived rewards. Diminished activity in this area is linked to impaired cognitive abilities, along with a decline in motivation and the ability to experience reward.
- The relative influence of the heteroreceptor and autoreceptor types is determined by a transcription factor Deaf1. This transcription factor has the effect of suppressing autoreceptor activity whilst simultaneously promoting heteroreceptor activity. A genetic polymorphism on rs6295 results in reduced binding of Deaf1 and an overexpression of the autoreceptor, and potentially represents a genetic vulnerability to developing negative symptoms from SSRIs.
- An optimal therapeutic strategy to alleviate symptoms would involve stimulating the heteroreceptor sites while simultaneously inhibiting the autoreceptor sites. Presynaptic antagonists such as Pindolol have been repeatedly demonstrated to remediate the some of the deleterious effects of SSRI treatment mood and cognition. Partial agonists such as Flibanserin or Buspirone might be effective in mitigating some symptoms, but they also exhibit pre-synaptic activity, which could limit their overall efficacy.
Related Articles
References
Click Arrow to Show References
[1] Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268626/
[2] Serotonin Signaling through Prefrontal Cortex 5-HT1A Receptors during Adolescence Can Determine Baseline Mood-Related Behaviors https://www.cell.com/cell-reports/pdf/S2211-1247(17)30058-X.pdf
[3] 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex https://www.sciencedirect.com/science/article/abs/pii/S0006322300008507
[4] Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies https://www.sciencedirect.com/science/article/pii/S0006322300009938
[5] https://www.cell.com/cell-reports/pdfExtended/S2211-1247(17)30058-X
[6] In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1098-2396(199808)29:4%3C392::AID-SYN11%3E3.0.CO;2-T
[7] Responsiveness of 5-HT1A and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition https://www.jpn.ca/content/jpn/30/4/268.full.pdf
[8] https://www.cell.com/cell-reports/pdf/S2211-1247(17)30058-X.pdf
[9] https://www.jpn.ca/content/jpn/30/4/268.full.pdf
[10] Aberrant orbitofrontal cortex reactivity to erotic cues in Compulsive Sexual Behavior Disorder https://akjournals.com/view/journals/2006/10/3/article-p646.xml?special=x3watch
[11] https://www.jpn.ca/content/jpn/30/4/268.full.pdf
[12]Kisspeptin signaling and nNOS neurons in the VMHvl modulate lordosis behavior but not mate preference in female mice https://www.sciencedirect.com/science/article/abs/pii/S0028390821003178
[13] Extracellular regulated protein kinaseis critical for the role of 5-HT1a receptor in modulating nNOS expression and anxiety-related behaviors https://www.sciencedirect.com/science/article/abs/pii/S0166432817307878
[14] Neuronal Nitric Oxide Synthase Alteration Accounts for the Role of 5-HT1A Receptor in Modulating Anxiety-Related Behaviors https://www.jneurosci.org/content/30/7/2433.short
[15] μ-opioid receptor availability is associated with sex drive in human males https://link.springer.com/article/10.3758/s13415-021-00960-3
[16] Transcriptional Regulation of the Human 5-HT1A Receptor Gene by Lithium: Role of Deaf1 and GSK3β https://www.mdpi.com/1422-0067/24/21/15620
[17] Association of the C(−1019)G 5-HT1A functional promoter polymorphism with antidepressant response https://academic.oup.com/ijnp/article/7/4/501/707937?login=false
[18] https://www.sciencedirect.com/science/article/abs/pii/0893133X9500240E
[19] https://www.sciencedirect.com/science/article/abs/pii/0893133X9500240E
[20] 5-HT1A receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats https://academic.oup.com/ijnp/article/12/8/1045/677907
[21] Antidepressant-like effects of sodium butyrate in combination with estrogen in rat forced swimming test: Involvement of 5-HT1A receptors https://www.sciencedirect.com/science/article/abs/pii/S016643280800497X
[22] Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488484/
[23] Involvement of 5-HT1A receptor-mediated histone acetylation in the regulation of depression https://www.ingentaconnect.com/content/wk/nerep/2021/00000032/00000012/art00012
[24] https://www.sciencedirect.com/science/article/abs/pii/S0893133X00001755
[25] https://academic.oup.com/ijnp/article/11/5/701/968740?login=false
[26] https://pmc.ncbi.nlm.nih.gov/articles/PMC1764545/
[27] https://pubmed.ncbi.nlm.nih.gov/25295433/
[28] https://www.nature.com/articles/1395951
Leave a Reply